Clinical Trials Outcomes Among Hypertensive Patients With Concomitant Peripheral and Coronary Artery Disease Findings From the INternational VErapamil-SR/Trandolapril STudy

Abstract—Hypertension is a common risk factor for peripheral arterial disease (PAD). Guidelines suggest treating PAD patients to a blood pressure 130/80 mm Hg; therefore, our objective was to explore whether attainment of this target blood pressure is associated with improved outcomes. We performed a post hoc analysis of the INternational VErapamil-SR/Trandolapril STudy, a randomized clinical trial, which included hypertensive patients with concomitant PAD and coronary artery disease. There were 2699 PAD patients followed for a mean of 2.7 years (60 970 patient-years). The primary outcome, all-cause death, nonfatal myocardial infarction, or nonfatal stroke, occurred in 16.3 % of PAD patients versus 9.2 % without PAD (adjusted hazard ratio: 1.26 [95 % CI: 1.13 to 1.40]; P0.0001). The primary outcome occurred least frequently among PAD patients treated to an average systolic blood pressure of 135 to 145 mm Hg and an average diastolic blood pressure of 60 to 90 mm Hg. PAD patients displayed a J-shape relationship with systolic blood pressure and the primary outcome, although individuals without PAD did not. PAD patients may require a different target blood pressure than those without PAD. (Hypertension. 2010;55:48-53.) Key Words: peripheral vascular disease peripheral arterial disease coronary artery disease hypertension prognosis calcium antagonist -blocker Screening programs have detected peripheral arterial dis-ease (PAD) in up to one fourth of individuals over the age of 50 years and/or with symptoms of claudication.1 In addition t